A universal recipient for protein production in eggs

描述(申请人提供)：到目前为止，嵌合鸡是通过将囊胚层细胞或胚胎干细胞注射到X期胚胎(接受者)中而制成的，但嵌合体的频率和水平是可变的和不可预测的(Petite等人，1990；Petitte等人，1993)。我们正在开发一种贡献最小的通用接受者，这样捐赠者来源的细胞对所产生的嵌合体的贡献就会一直很高，而且是可以预测的。这些高级嵌合体一旦开始产蛋，在将编码生物制药蛋白的基因传递给下一代之前，就可以用来在鸡蛋中产生生物制药蛋白。此外，如果转基因干扰了生物制药蛋白的繁殖能力，这些高级嵌合体将允许生产生物制药蛋白。这项研究的终点是一个强大的系统，以高度可预测的方式产生高等级嵌合体。使用该系统可以快速、可扩展的系统以最低的成本生产生物制药蛋白质。

DESCRIPTION (provided by applicant): To date, chimeric chickens are made by injecting blastodermal cells or embryonic stem cells into the stage X embryo (recipient), but the frequency and level of chimerism is variable and unpredictable (Petitte et al., 1990; Petitte et al., 1993). We are developing a universal recipient that contributes minimally, so that the contribution of donor derived cells to the resulting chimera is constantly high and predictable. These high-grade chimeras can be used to produce biopharmaceutical proteins in chicken eggs as soon as the chimeras commence laying and before they transmit the gene encoding the biopharmaceutical protein to the next generation. In addition, these high-grade chimeras will allow the production of biopharmaceutical proteins if the transgene interferes with their ability to reproduce. The end point of this research is a robust system to produce high-grade chimeras in highly predictable way. Using this system biopharmaceutical proteins can be produced quickly, in a scalable system and at minimal cost.